Retro-inversion peptides that target GIT receptors and related methods
View Patent ↗Retro-inverted forms of GIT targeting agents that target specific receptor sites in vivo and/or promote uptake of active agents and/or enhance active agent delivery across the GIT into the systemic circulation are provided. These retro-inverted peptides and compositions containing these retro-inverted peptides can be used to deliver an active agent, such as a drug or a drug-containing nano- or microparticle for treatment of a condition in a subject in need of the drug, in vivo. Additionally, the invention provides antibodies which are capable of immunospecifically binding the retro-inverted peptides.
1. A d-form retro-inverted peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 (ZElan144), SEQ ID NO:2 (ZElan145), and SEQ ID NO:3 (ZElan146) wherein said peptide binds to a domain of a gastro-intestinal tract transport receptor selected from the group consisting of amino acids 29-273 of human intestinal oligopeptide transporter (HPT1), amino acids 391-571 of human oligopeptide transporter (hPEPT1), amino acids 387-685 of human D2 clone (D2H), and amino acids 272-667 of human sucrase isomaltose (hSI), wherein said peptide is no more than 50 amino acid residues.
2. The peptide of claim 1 , wherein the peptide is no more than 40 amino acid residues.
3. The peptide of claim 1 , wherein the peptide is no more than 30 amino acid residues.
4. The peptide of claim 1 , wherein the peptide is no more than 20 amino acid residues.
5. A pharmaceutical composition comprising a therapeutically effective amount of a composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.
6. A composition comprising the peptide of claim 1 , wherein the peptide is coated onto the surface of a nanoparticle or microparticle, absorbed onto the surface of a nanoparticle or microparticle, or covalently bonded to the surface of a nanoparticle or microparticle.
7. A nanoparticle or microparticle formed from the peptide of claim 1 .